Literature DB >> 2805263

Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients.

L Fananapazir1, C M Tracy, M B Leon, J B Winkler, R O Cannon, R O Bonow, B J Maron, S E Epstein.   

Abstract

Electrophysiologic studies (EPS) were performed in 155 patients with hypertrophic cardiomyopathy (HCM). Indications for EPS were cardiac arrest in 22 patients, syncope in 55 patients, presyncope in 37 patients, asymptomatic ventricular tachycardia (VT) in 24 patients, palpitations in 10 patients, and a strong family history of sudden cardiac death in seven patients. Thirty-five (23%) patients had significant resting left ventricular outflow tract obstruction. Electrophysiologic abnormalities were present in 126 (81%) patients. A high prevalence of abnormal sinus-node function (66%) and His-Purkinje (HV) conduction (30%) was noted. The most commonly induced supraventricular arrhythmias were atrial reentrant tachycardia and atrial fibrillation (10% and 11% of patients, respectively). Accessory atrioventricular pathways were present in seven (5%) patients. Programmed ventricular stimulation (PVS) induced nonsustained ventricular tachycardia in 22 (14%) patients and sustained ventricular arrhythmia in 66 (43%) patients. Sustained ventricular arrhythmia was polymorphic VT in 48 (73%) patients, monomorphic VT in 16 (24%) patients, and ventricular fibrillation in two (3%) patients. Induction was with two premature stimuli in 19 (29%) patients and three premature stimuli in 47 (71%) patients. Of 17 cardiac arrest survivors with sustained ventricular arrhythmia, 16 (94%) patients required three premature stimuli for arrhythmia induction. Sustained ventricular arrhythmia was induced at a right ventricular site in 51 (77%) patients and at a left ventricular site in 15 (23%) patients. Univariate analysis showed a significant (p less than 0.05) association between inducibility of sustained ventricular arrhythmia and VT on Holter in patients with a history of cardiac arrest or syncope but not in patients with presyncope or asymptomatic patients. Multivariate logistic regression analysis revealed that the following were significantly associated with inducibility of sustained ventricular arrhythmia: clinical presentation (cardiac arrest more than syncope more than presyncope more than asymptomatic patients, p = 0.0002; chronic or inducible atrial fibrillation, p = 0.002; and male gender, p = 0.04). In contrast, there was no clinical correlate of induced nonsustained VT.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2805263     DOI: 10.1161/01.cir.80.5.1259

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  27 in total

Review 1.  Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death.

Authors:  William J McKenna; Elijah R Behr
Journal:  Heart       Date:  2002-02       Impact factor: 5.994

2.  Unmasking the truth.

Authors:  D Cullington; S Esmail; S Hurren; J G F Cleland; A L Clark; M F Alamgir
Journal:  BMJ Case Rep       Date:  2011-01-12

3.  Malignant familial hypertrophic cardiomyopathy in a family with a 453Arg-->Cys mutation in the beta-myosin heavy chain gene: coexistence of sudden death and end-stage heart failure.

Authors:  Y L Ko; J J Chen; T K Tang; J J Cheng; S Y Lin; Y C Liou; P Kuan; C W Wu; W P Lien; C C Liew
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

Review 4.  Problems in diagnosis and management of hypertrophic cardiomyopathy.

Authors:  O Odemuyiwa; W J McKenna
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

5.  Sustained bundle branch reentry in a patient with hypertrophic cardiomyopathy and nondilated left ventricle.

Authors:  S Mittal; R F Coyne; I M Herling; D Z Kocovic; B B Pavri
Journal:  J Interv Card Electrophysiol       Date:  1997-02       Impact factor: 1.900

Review 6.  The effects of septal myectomy and alcohol septal ablation for hypertrophic cardiomyopathy on the cardiac conduction system.

Authors:  Patrick Fitzgerald; Fred Kusumoto
Journal:  J Interv Card Electrophysiol       Date:  2018-08-10       Impact factor: 1.900

7.  Hypertrophic Cardiomyopathy.

Authors:  Elijah R. Behr; William J. McKenna
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-12

Review 8.  Insights and challenges in hypertrophic cardiomyopathy, 2012.

Authors:  Srijita Sen-Chowdhry; María Teresa Tomé Esteban; William J McKenna
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2012-09-25

9.  Determinants of peak oxygen uptake in patients with hypertrophic cardiomyopathy: a single-center study.

Authors:  Damiano Magrì; Piergiuseppe Agostoni; Filippo Maria Cauti; Beatrice Musumeci; Gabriele Egidy Assenza; Carlo Nicola De Cecco; Giuseppe Muscogiuri; Antonello Maruotti; Agnese Ricotta; Erika Pagannone; Laura Marino; Daria Santini; Giulia Proietti; Andrea Serdoz; Francesco Paneni; Massimo Volpe; Camillo Autore
Journal:  Intern Emerg Med       Date:  2012-10-07       Impact factor: 3.397

10.  Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events.

Authors:  Jeffrey P Moak; Eric S Leifer; Dorothy Tripodi; Saidi A Mohiddin; Lameh Fananapazir
Journal:  Pediatr Cardiol       Date:  2011-04-13       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.